B
Bonne Biesma
Researcher at Bosch
Publications - 105
Citations - 8431
Bonne Biesma is an academic researcher from Bosch. The author has contributed to research in topics: Lung cancer & Chemotherapy. The author has an hindex of 36, co-authored 101 publications receiving 7953 citations. Previous affiliations of Bonne Biesma include Katholieke Universiteit Leuven & Gdańsk Medical University.
Papers
More filters
Journal ArticleDOI
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti,Purvish M. Parikh,Joachim von Pawel,Bonne Biesma,Johan Vansteenkiste,Christian Manegold,Piotr Serwatowski,Ulrich Gatzemeier,Raghunadharao Digumarti,Mauro Zukin,Jin S. Lee,Anders Mellemgaard,Keunchil Park,Shehkar Patil,Janusz Rolski,Tuncay Göksel,Filippo de Marinis,Lorinda Simms,Katherine P. Sugarman,David R. Gandara +19 more
TL;DR: This is the first prospective phase III study in NSCLC to show survival differences based on histologic type and cisplatin/pemetrexed provides similar efficacy with better tolerability and more convenient administration than cis platin/gemcitabine.
Journal ArticleDOI
Randomized Controlled Trial of Resection Versus Radiotherapy After Induction Chemotherapy in Stage IIIA-N2 Non–Small-Cell Lung Cancer
Jan P. van Meerbeeck,Gijs W. P. M. Kramer,Paul Van Schil,Catherine Legrand,Egbert F. Smit,Franz M.N.H. Schramel,Vivianne C. G. Tjan-Heijnen,Bonne Biesma,C. Debruyne,Nico van Zandwijk,Ted A.W. Splinter,Giuseppe Giaccone +11 more
TL;DR: In selected patients with pathologically proven stage IIIA-N2 NSCLC and a response to induction chemotherapy, surgical resection did not improve overall or progression-free survival compared with radiother- apy, and radiotherapy should be considered the preferred locoregional treatment for these patients.
Journal ArticleDOI
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Roy S. Herbst,Yan Sun,Wilfried Eberhardt,Paul Germonpré,Nagahiro Saijo,Caicun Zhou,Jie Wang,Longyun Li,Fairooz F. Kabbinavar,Yukito Ichinose,Shukui Qin,Li Zhang,Bonne Biesma,John V. Heymach,Peter Langmuir,Sarah J. Kennedy,Hiroomi Tada,Bruce E. Johnson +17 more
TL;DR: The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy, supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).
Journal ArticleDOI
Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975
Egbert F. Smit,Jan P. van Meerbeeck,Pilar Lianes,C. Debruyne,Catherine Legrand,Franz M.N.H. Schramel,Hans Smit,Rabab Gaafar,Bonne Biesma,Chris Manegold,Niels Neymark,Giuseppe Giaccone +11 more
TL;DR: Gemcitabine plus cisplatin and paclitaxel plus gem citabine do not increase overall survival in patients with advanced NSCLC as compared with paclitrixel plus cisPlatin, and costs associated with the nonplatinum arm were highest.
Journal ArticleDOI
PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non–Small-Cell Lung Cancer
Suresh Senan,Anthony Brade,Lu Hua Wang,Johan Vansteenkiste,Shaker R. Dakhil,Bonne Biesma,Maite Martinez Aguillo,Joachim G.J.V. Aerts,Ramaswamy Govindan,Belén Rubio-Viqueira,Conrad R. Lewanski,David R. Gandara,Hak Choy,Tony Mok,Anwar Hossain,Neill Iscoe,Joseph Treat,Andrew Koustenis,Belen San Antonio,Nadia Chouaki,Everett E. Vokes +20 more
TL;DR: Pemetrexed-cisplatin combined with TRT followed by consolidation pemetrexe was not superior to standard chemoradiotherapy for stage III unresectable nonsquamous non-small-cell lung cancer.